Exploration of biomarkers to predict the efficacy of immune checkpoint inhibitors in gastric cancer using cell-free RNA.

Exploration of biomarkers to predict the efficacy of immune checkpoint inhibitors in gastric cancer using cell-free RNA. - Exploration of biomarkers to predict the efficacy of immune checkpoint inhibitors in gastric cancer using cell-free RNA.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047448

Enrollment

Registered

2022-04-10

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants of VOYAGER study (jRCTs071190025)

Exclusion criteria

Exclusion criteria: Inappropriate participants

Design outcomes

Primary

Measure	Time frame
To explore biomarkers for predicting the response of nivolumab in gastric cancer.	—

Secondary

Measure	Time frame
Association of peripheral blood cfRNA with progression-free survival (PFS) Association of Peripheral Blood cfRNA with Overall Survival (OS) Association of Adverse Events (AEs) with cfRNA in Peripheral Blood Time to treatment success (TTF) in relation to peripheral blood cfRNA Disease Control Rate (DCR) and Peripheral Blood cfRNA Association between quality of life and peripheral blood cfRNA	—

Countries

Japan

Contacts

Public ContactQingjiang Hu

Kyushu University Hospital Department of Surgery and Science

hu.qingjiang.714@m.kyushu-u.ac.jp092-642-5466

Outcome results